Loading...
 

Volume 34, Issue 4, December 2023



Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2022;33(2):237-40
Canakinumab might be Protective against Severe COVID-19 for Patients with Autoinflammatory Disorders
Authors Information

1Cerrahpasa Medical Faculty, University of Istanbul-Cerrahpasa, Istanbul, Turkey

2Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul-Cerrahpasa, Istanbul, Turkey

S Ugurlu

References
  1. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al.  Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses 2020 Mar 27;12(4):372.
  2. Ozdogan H, Ugurlu S. Familial Mediterranean Fever. Presse Med. 2019;48(1 Pt 2):e61-e76.
  3. Cimaz R. Systemic-onset juvenile idiopathic arthritis. Autoimmun Rev 2016 Sep;15(9):931-4.
  4. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still's disease. Autoimmun Rev 2014 Jul;13(7):708-22.
  5. Dimopoulos G, de Mast Q, Markou N,  et al. Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis. Cell Host Microbe. 2020 Jul 8;28(1):117-123.e1.
  6. Aouba A, Baldolli A, Geffray L, Theodorakopoulou M, Komnos A, Mouktaroudi M, et al.  Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Ann Rheum Dis 2020 Oct;79(10):1381-1382.
  7. Pontali E, Volpi S, Antonucci G, Castellaneta M, Buzzi D, Tricerri F, et al. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. J Allergy ClinImmunol 2020 Jul;146(1):213-215.
  8. Sheng CC, Sahoo D, Dugar S, Prada RA, Wang TKM, Abou Hassan OK, et al. Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study). Clin Cardiol 2020 Oct;43(10):1055-63.
  9. Ucciferri C, Auricchio A, Di Nicola M, Potere N, Abbate A, Cipollone F, et al. Canakinumab in a subgroup of patients with COVID-19. Lancet Rheumatol 2020 Aug;2(8):e457-ee458.
  10. Lara PC, Macías-Verde D, Burgos-Burgos J. Age-induced NLRP3 Inflammasome Over-activation Increases Lethality of SARS-CoV-2 Pneumonia in Elderly Patients. Aging Dis 2020 Jul 23;11(4):756-762.
  11. Freeman TL, Swartz TH. Targeting the NLRP3 Inflammasome in Severe COVID-19. Front Immunol 2020 Jun 23;11:1518.
  12. van den Berg DF, TeVelde AA. Severe COVID-19: NLRP3 Inflammasome Dysregulated. Front Immunol 2020 Jun 26;11:1580.
  13. Stella A, Lamkanfi M, Portincasa P. Familial Mediterranean Fever and COVID-19: Friends or Foes? Front Immunol 2020 Sep 18;11:574593.
  14. Gajendran M, Perisetti A, Aziz M, Raghavapuram S, Bansal P, Tharian B, Goyal H. Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned. Ann Gastroenterol 2020 Nov-Dec;33(6):591-602.
  15. Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol 2020 Jul;39(7):2085-94.
  16. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. J Infect 2020 Jun;80(6):607-13.
  17. Landi L, Ravaglia C, Russo E, Cataleta P, Fusari M, Boschi A, et al. Blockage of interleukin-1β with canakinumab in patients with Covid-19. Sci Rep 2020 Dec 11;10(1):21775.